Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2019
Event: Closing of a previously announced public offering of equity securities.
Key Financial Metrics
This filing reports the closing of a capital raise but does not provide specific financial metrics such as revenue, profit, cash flow, margins, or debt levels. The filing text does not provide a clear value for the total proceeds raised or the specific pricing of the securities.
| Security Type | Quantity Issued |
|---|---|
| Common Stock | 531,173 shares |
| Pre-funded Warrants | Up to 3,608,304 (each to purchase one share) |
| Common Warrants | Up to 4,139,477 (each to purchase one share) |
Material Changes
The primary material change is the expansion of the company's capital structure through the issuance of new equity and warrant instruments. This event increases the number of shares outstanding and potential future dilution upon the exercise of warrants.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) regarding the closing of the offering but does not include specific management commentary, forward-looking guidance, or risk factors within the text of this 8-K form.
Unusual Items: The offering structure includes a significant volume of pre-funded warrants and common warrants relative to the direct common stock issuance.
Investor Verification Checklist
- Verify the total gross proceeds raised from the offering by reviewing the attached press release (Exhibit 99.1) or the related Prospectus Supplement.
- Confirm the exercise price and expiration dates for the 3,608,304 pre-funded warrants and 4,139,477 common warrants.
- Assess the immediate impact on total shares outstanding and potential dilution to existing shareholders.
- Review the intended use of proceeds as stated in the offering documents.